Research ArticleOriginal Research

Low-Dose Aspirin Use Among African American Older Adults

Mohsen Bazargan, Cheryl Wisseh, Edward Adinkrah, Shanika Boyce, Ebony O. King and Shervin Assari
The Journal of the American Board of Family Medicine January 2021, 34 (1) 132-143; DOI: https://doi.org/10.3122/jabfm.2021.01.200322

References

  1. 1.↵
    American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2020. Diabetes Care 2020;43:S111–S134.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Bibbins-Domingo K,
    2. Force U
    . Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2016;164:836–45.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Baigent C,
    2. Blackwell L,
    3. Collins R,
    4. et al
    . Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849–60.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989;321:129–35.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Emilsson L,
    2. Holme Ø,
    3. Bretthauer M,
    4. et al
    . Systematic review with meta‐analysis: the comparative effectiveness of aspirin vs. screening for colorectal cancer prevention. Aliment Pharmacol Ther 2017;45:193–204.
    OpenUrl
  6. 6.↵
    1. Qiao Y,
    2. Yang T,
    3. Gan Y,
    4. et al
    . Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. BMC Cancer 2018;18:288.
    OpenUrlCrossRef
  7. 7.↵
    1. Sauer C,
    2. Myran D,
    3. Costentin C,
    4. et al
    . Effect of long-term aspirin use on the incidence of prostate cancer: a systematic review and meta-analysis. Crit Rev Oncol/Hematol 2018;132:66–75.
    OpenUrl
  8. 8.↵
    1. Lu L,
    2. Shi L,
    3. Zeng J,
    4. Wen Z
    . Aspirin as a potential modality for the chemoprevention of breast cancer: a dose-response meta-analysis of cohort studies from 857,831 participants. Oncotarget 2017;8:40389–401.
    OpenUrlCrossRef
  9. 9.↵
    1. Huang XZ,
    2. Chen Y,
    3. Wu J,
    4. et al
    . Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: a dose-response meta-analysis. Oncotarget 2017;8:4781–95.
    OpenUrl
  10. 10.↵
    1. Group ASC,
    2. Bowman L,
    3. Mafham M,
    4. et al
    . Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018;379:1529–39.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Gaziano JM,
    2. Brotons C,
    3. Coppolecchia R,
    4. et al
    . Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018;392:1036–46.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Tillman H,
    2. Johnston SC,
    3. Farrant M,
    4. et al
    . Risk for major hemorrhages in patients receiving clopidogrel and aspirin compared with aspirin alone after transient ischemic attack or minor ischemic stroke: a secondary analysis of the POINT randomized clinical trial. JAMA Neurol 2019;76:774–82.
    OpenUrl
  13. 13.↵
    1. Sugawara M,
    2. Goto Y,
    3. Yamazaki T,
    4. et al
    . Low-dose aspirin for primary prevention of cardiovascular events in elderly Japanese patients with atherosclerotic risk factors: subanalysis of a randomized clinical trial (JPPP-70). Am J Cardiovasc Drugs 2019;19:299–311.
    OpenUrl
  14. 14.↵
    1. Lin MH,
    2. Lee CH,
    3. Lin C,
    4. et al
    . Low-dose aspirin for the primary prevention of cardiovascular disease in diabetic individuals: a meta-analysis of randomized control trials and trial sequential analysis. J Clin Med 2019;8:609.
  15. 15.↵
    1. VanWormer JJ,
    2. Greenlee RT,
    3. McBride PE,
    4. et al
    . Aspirin for primary prevention of CVD: are the right people using it? J Fam Pract 2012;61:525–32.
    OpenUrlPubMed
  16. 16.↵
    1. Fernandez-Ruiz I
    . Aspirin for primary prevention of CVD: a matter of balance. Nat Rev Cardiol 2018;15:651.
    OpenUrl
  17. 17.↵
    1. Fletcher RH
    . Review: aspirin for CVD primary prevention increases gastrointestinal bleeding and hemorrhagic stroke. Ann Intern Med 2016;165:JC17.
    OpenUrl
  18. 18.↵
    1. Luepker RV,
    2. Steffen LM,
    3. Duval S,
    4. Zantek ND,
    5. Zhou X,
    6. Hirsch AT
    . Population trends in aspirin use for cardiovascular disease prevention 1980–2009: the Minnesota Heart Survey. JAHA 2015;4:e002320.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Morgan G,
    2. Brown T
    . Benefits and risk of aspirin as primary prevention of cardiovascular disease. ARxCH 2019;3(1).
  20. 20.↵
    1. Arnett DK,
    2. Blumenthal RS,
    3. Albert MA,
    4. et al
    . ACC/AHA guideline on the primary prevention of cardiovascular disease. J Am Coll Cardiol 2019;140:e596–e646.
    OpenUrl
  21. 21.↵
    Centers for Disease Control and Prevention. Heart disease facts. 2020. Available from: https://wwwcdcgov/heartdisease/facts.htm. Accessed July 2020.
  22. 22.↵
    1. Kochanek KD,
    2. Murphy SL,
    3. Xu J,
    4. Arias E
    . National Vital Statistics Reports - Deaths: Final Data for 2017 - Volume 68, Number 9. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_09-508.pdf. Accessed November 2020.
  23. 23.↵
    1. Howard G,
    2. Safford MM,
    3. Moy CS,
    4. et al
    . Racial differences in the incidence of cardiovascular risk factors in older black and white adults. J Am Geriatr Soc 2017;65:83–90.
    OpenUrl
  24. 24.↵
    Center for Medicare & Medicaid Services. Chronic conditions overview—Prevalence state level: all beneficiaries by race/ethnicity and age, 2007–2017. Available from: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Chronic-Conditions/MCC_Main. Accessed November 2020.
  25. 25.↵
    1. Yazdanshenas H,
    2. Bazargan M,
    3. Smith J,
    4. Martins D,
    5. Motahari H,
    6. Orum G
    . Pain treatment of underserved older African Americans. J Am Geriatr Soc 2016;64:2116–21.
    OpenUrl
  26. 26.↵
    1. Gu Q,
    2. Burt VL,
    3. Dillon CF,
    4. Yoon S
    . Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension. Circulation 2012;126:2105–14.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Kirk JK,
    2. D’Agostino RB Jr.,
    3. Bell RA,
    4. et al
    . Disparities in HbA1c levels between African-American and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care 2006;29:2130–6.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Park SY,
    2. Wilkens LR,
    3. Kolonel LN,
    4. Monroe KR,
    5. Haiman CA,
    6. Marchand LL
    . Exploring differences in the aspirin-colorectal cancer association by sex and race/ethnicity: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2017;26:162–9.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Sanchez DR,
    2. Diez Roux AV,
    3. Michos ED,
    4. et al
    . Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of coronary heart disease from the multi-ethnic study of atherosclerosis. Am J Cardiol 2011;107:41–6.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Mauer AC,
    2. Khazanov NA,
    3. Levenkova N,
    4. et al
    . Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults. J Thromb Haemost 2011;9:100–8.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Brown DW,
    2. Shepard D,
    3. Giles WH,
    4. Greenlund KJ,
    5. Croft JB
    . Racial differences in the use of aspirin: an important tool for preventing heart disease and stroke. Ethn Dis 2005;15:620–6.
    OpenUrlPubMed
  32. 32.↵
    1. Van’t Hof JR,
    2. Duval S,
    3. Misialek JR,
    4. et al
    . Aspirin use for cardiovascular disease prevention in an African American population: prevalence and associations with health behavior beliefs. J Commun Health 2019;44:561–8.
    OpenUrl
  33. 33.↵
    Los Angeles County Department of Health: Office of Health Assessment and Epidemiology. Key indicators by services planning area. 2017. Available from: http://publichealth.lacounty.gov/ha/docs/2015lachs/keyindicator/ph-kih_2017-sec%20updated.pdf. Accessed July 2020.
  34. 34.↵
    1. Jianhui X,
    2. Teutsch S,
    3. Braun P,
    4. et al
    . The 2015 Los Angeles healthy aging report. Los Angeles, CA: USC Edward R. Roybal Institute on Aging; 2015.
  35. 35.↵
    1. Laaksonen E,
    2. Lallukka T,
    3. Lahelma E,
    4. et al
    . Economic difficulties and physical functioning in Finnish and British employees: contribution of social and behavioural factors. Eur J Public Health 2011;21:456–62.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    1. Sorensen L,
    2. Stokes JA,
    3. Purdie DM,
    4. Woodward M,
    5. Roberts MS
    . Medication management at home: medication risk factor prevalence and inter-relationships. J Clin Pharm Ther 2006;31:485–91.
    OpenUrlPubMed
  37. 37.↵
    1. Bazargan M,
    2. Smith J,
    3. Movassaghi M,
    4. et al
    . Polypharmacy among underserved older African American adults. J Aging Res 2017;2017:6026358.
    OpenUrl
  38. 38.↵
    1. Bazargan M,
    2. Smith J,
    3. Saqib M,
    4. Helmi H,
    5. Assari S
    . Associations between polypharmacy, self-rated health, and depression in African American older adults; mediators and moderators. Int J Environ Res Public Health 2019;16:1574.
    OpenUrl
  39. 39.↵
    1. Bazargan M,
    2. Smith J,
    3. Yazdanshenas H,
    4. Movassaghi M,
    5. Martins D,
    6. Orum G
    . Non-adherence to medication regimens among older African-American adults. BMC Geriatr 2017;17:163.
    OpenUrl
  40. 40.↵
    International Business Machines Cop (IBM). IBM Micromedex with Watson. Available from: https://wwwibmcom/products/micromedex-with-watson/details. Assessed December 5, 2019.
  41. 41.↵
    1. Kheshti R,
    2. Aalipour M,
    3. Namazi S
    . A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract 2016;5:257–63.
    OpenUrl
  42. 42.↵
    1. Fang J,
    2. George MG,
    3. Gindi RM,
    4. et al
    . Use of low-dose aspirin as secondary prevention of atherosclerotic cardiovascular disease in US adults (from the National Health Interview Survey, 2012). Am J Cardiol 2015;115:895–900.
    OpenUrl
  43. 43.↵
    1. O’Brien CW,
    2. Juraschek SP,
    3. Wee CC
    . Prevalence of aspirin use for primary prevention of cardiovascular disease in the united states: results from the 2017 National Health Interview Survey. Ann Intern Med 2019;171:596–8.
    OpenUrl
  44. 44.↵
    1. Grundy SM,
    2. Stone NJ,
    3. Bailey AL,
    4. et al
    . 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;73:e285–e350.
    OpenUrlFREE Full Text
  45. 45.↵
    Centers for Disease Control and Prevention. African American health. 2017. Available from: https://www.cdc.gov/vitalsigns/aahealth/index.html. Accessed July 2020.
  46. 46.↵
    1. Qato DM,
    2. Lindau ST,
    3. Conti RM,
    4. Schumm LP,
    5. Alexander GC
    . Racial and ethnic disparities in cardiovascular medication use among older adults in the United States. Pharmacoepidemiol Drug Saf 2010;19:834–42.
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Hanlon JT,
    2. Perera S,
    3. Newman AB,
    4. et al
    . Potential drug-drug and drug–disease interactions in well‐functioning community‐dwelling older adults. J Clin Pharm Ther 2017;42:228–33.
    OpenUrl
  48. 48.↵
    1. Guirguis-Blake JM,
    2. Evans CV,
    3. Senger CA,
    4. O’Connor EA,
    5. Whitlock EP
    . Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the US Preventive Services Task Force. Ann Intern Med 2016;164:804–13.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Reeve E,
    2. Wolff JL,
    3. Skehan M,
    4. Bayliss EA,
    5. Hilmer SN,
    6. Boyd CM
    . Assessment of attitudes toward deprescribing in older Medicare beneficiaries in the United States. JAMA Intern Med 2018;178:1673–80.
    OpenUrl
  50. 50.↵
    1. Palagyi A,
    2. Keay L,
    3. Harper J,
    4. Potter J,
    5. Lindley RI
    . Barricades and brick walls–A qualitative study exploring perceptions of medication use and deprescribing in long-term care. BMC Geriatr 2016;16:15.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Alrasheed MM,
    2. Alhawassi TM,
    3. Alanazi A,
    4. Aloudah N,
    5. Khurshid F,
    6. Alsultan M
    . Knowledge and willingness of physicians about deprescribing among older patients: a qualitative study. Clin Interv Aging 2018;13:1401–8.
    OpenUrl
  52. 52.↵
    1. Anderson K,
    2. Stowasser D,
    3. Freeman C,
    4. Scott I
    . Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open 2014;4:e006544
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    1. Anderson K,
    2. Foster M,
    3. Freeman C,
    4. Luetsch K,
    5. Scott I
    . Negotiating “unmeasurable harm and benefit”: perspectives of general practitioners and consultant pharmacists on deprescribing in the primary care setting. Qual Health Res 2017;27:1936–47.
    OpenUrlCrossRef
  54. 54.↵
    1. Wallis KA,
    2. Andrews A,
    3. Henderson M
    . Swimming against the tide: primary care physicians’ views on deprescribing in everyday practice. Ann Fam Med 2017;15:341–6.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords